secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0000950170-22-011570
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics shareholders reject authorized capital increase; approve stock plan amendment
--------------------------------------------------------------------------------

- Proposal 10 to adjust authorized share capital and extend date for capital increase was not approved (37.0M for, 18.8M against).
- Amendment to 2018 Stock Plan approved, adding 1.7M common shares for issuance under the plan.
- Maria Fardis, Ph.D. elected as new board member; all nine incumbent directors re-elected.
- Binding advisory votes on executive compensation approved; frequency of say-on-pay set at one year.
- All other proposals passed, including re-election of auditors and independent voting representative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022011570/0000950170-22-011570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022011570/crsp-20220609.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer